Danaher (NYSE:DHR) PT Raised to $270.00

Danaher (NYSE:DHR) had its price target upped by stock analysts at Bank of America from $258.00 to $270.00 in a research note issued on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the conglomerate’s stock. Bank of America‘s price objective would suggest a potential upside of 9.84% from the stock’s previous close.

A number of other equities analysts have also recently commented on the stock. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 31st. Robert W. Baird boosted their price target on shares of Danaher from $259.00 to $271.00 and gave the stock an “outperform” rating in a research note on Wednesday. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. Finally, Citigroup upped their price objective on shares of Danaher from $255.00 to $280.00 and gave the company a “buy” rating in a research note on Wednesday, January 31st. Six equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $270.00.

Danaher Stock Performance

Danaher stock opened at $245.82 on Wednesday. The firm’s 50 day simple moving average is $248.94 and its 200 day simple moving average is $230.88. The company has a current ratio of 1.68, a quick ratio of 1.37 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $182.04 billion, a PE ratio of 41.66, a price-to-earnings-growth ratio of 4.24 and a beta of 0.83. Danaher has a 1-year low of $182.09 and a 1-year high of $259.00.

Danaher (NYSE:DHR) last posted its earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping analysts’ consensus estimates of $1.72 by $0.20. The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.62 billion. Danaher had a net margin of 16.78% and a return on equity of 11.48%. Danaher’s revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.36 EPS. As a group, analysts expect that Danaher will post 7.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Danaher news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of the stock in a transaction dated Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total value of $11,756,953.50. Following the completion of the transaction, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 2,622 shares of the stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the transaction, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The disclosure for this sale can be found here. In the last ninety days, insiders sold 84,132 shares of company stock worth $21,022,795. 11.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Founders Financial Securities LLC bought a new stake in Danaher during the 3rd quarter valued at about $218,000. GHP Investment Advisors Inc. boosted its holdings in shares of Danaher by 540.0% during the 3rd quarter. GHP Investment Advisors Inc. now owns 160 shares of the conglomerate’s stock valued at $40,000 after acquiring an additional 135 shares during the last quarter. Meridian Wealth Management LLC boosted its holdings in shares of Danaher by 99.5% during the 3rd quarter. Meridian Wealth Management LLC now owns 3,264 shares of the conglomerate’s stock valued at $810,000 after acquiring an additional 1,628 shares during the last quarter. Strategic Blueprint LLC boosted its holdings in shares of Danaher by 6.0% during the 3rd quarter. Strategic Blueprint LLC now owns 8,446 shares of the conglomerate’s stock valued at $2,096,000 after acquiring an additional 480 shares during the last quarter. Finally, Koshinski Asset Management Inc. boosted its holdings in shares of Danaher by 16.2% during the 3rd quarter. Koshinski Asset Management Inc. now owns 1,118 shares of the conglomerate’s stock valued at $277,000 after acquiring an additional 156 shares during the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.